항감염제 시장 규모, 점유율, 성장 분석 : 종류별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Anti-Infective Agents Market size was valued at USD 135.43 Billion in 2024 and is poised to grow from USD 137.61 Billion in 2025 to USD 156.37 Billion by 2033, growing at a CAGR of 1.61% during the forecast period (2026-2033).

The global anti-infective agents market is primarily driven by the increasing prevalence of infectious diseases, prompting continuous innovation in antibiotics, antivirals, antifungals, and antiparasitics. This market encompasses prescription medications, over-the-counter products, and biologics aimed at preventing and treating infections, with rising antimicrobial resistance contributing significantly to demand. The shift from broad-spectrum antibiotics to targeted therapies such as small molecules and monoclonal antibodies highlights the evolution in treatment approaches. Furthermore, ineffective legacy drugs lead to increased morbidity, extended hospital stays, and higher healthcare costs, spurring investment in novel therapeutics and rapid diagnostic tools. Regulatory incentives and public-private partnerships are vital in transforming urgent needs into opportunities, expanding access in emerging markets, and supporting sustainable growth through integrated diagnostics and stewardship initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti-Infective Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anti-Infective Agents Market Segments Analysis

Global anti-infective agents market is segmented by type, route of administration, end-user and region. Based on type, the market is segmented into antibacterial agents, antiviral agents, antifungal agents and others. Based on route of administration, the market is segmented into oral, parenteral, topical and others. Based on end-user, the market is segmented into hospitals, homecare settings, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Anti-Infective Agents Market

The growing challenge of antimicrobial resistance is driving a surge in the development of new and enhanced anti-infective agents. This escalating issue has prompted numerous companies and research institutions to focus on innovative prevention and treatment strategies. The competitive healthcare landscape fosters investment opportunities in discovery, clinical development, and pipeline expansion. Moreover, it paves the way for collaborative partnerships and licensing agreements aimed at accelerating product cycles and market entry. This heightened emphasis on innovation is set to yield a variety of new therapeutic options, thereby stimulating commercial activity across diverse sectors of the economy.

Restraints in the Global Anti-Infective Agents Market

One significant constraint impacting the Global Anti-Infective Agents market is the substantial financial investment required for the research and development of new drugs, coupled with the costs associated with conducting clinical trials and obtaining regulatory approvals. This financial burden deters many companies from entering the anti-infective sector. Furthermore, the lengthy process of drug development and the inherent uncertainties regarding market success create an environment where justifying such investments becomes increasingly challenging. As a result, fewer new drugs are emerging from the development pipeline, leading to a decline in the number of active projects and prompting companies to consolidate their resources to focus on a more limited range of offerings.

Market Trends of the Global Anti-Infective Agents Market

The Global Anti-Infective Agents market is increasingly influenced by the integration of precision therapy, characterized by the emergence of molecular profiling and pathogen-specific biomarker discovery. This shift enables the customization of anti-infective treatment regimens tailored to individual patient profiles, fostering the development of narrow-spectrum products and host-targeted therapies. Pharmaceutical companies are leveraging clinical innovations such as companion diagnostics and tailored trial designs, aligning anti-infective therapy with specific pathogen attributes. This trend is fostering collaborative efforts among diagnostics, biotechnology firms, and healthcare providers, aimed at accelerating the adoption of targeted therapeutic strategies and enhancing clinical outcomes in the management of infectious diseases.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Anti-infective Agents Market Size by Type & CAGR (2026-2033)

• Market Overview
• Antibacterial Agents
• Antiviral Agents
• Antifungal Agents
• Others

Global Anti-infective Agents Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Topical
• Others

Global Anti-infective Agents Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare Settings
• Clinics
• Others

Global Anti-infective Agents Market Size & CAGR (2026-2033)

• North America (Type, Route of Administration, End-User)
  • US
  • Canada
• Europe (Type, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Route of Administration, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations